23384-72-7

Basic information

• Product Name: 3',4'-DIFLUOROPROPIOPHENONE
• Synonyms: 1-(3,4-Difluorophenyl)-1-propanone;Propiophenone, 3',4'-difluoro-;3',4'-DIFLUOROPROPIOPHENONE;3,4-DIFLUOROPROPIOPHENONE;3',4'-Difluoropropiophenone 97%;3',4'-Difluoropropiophenone97%;1-(3,4-difluorophenyl)propan-1-one
• CAS NO: 23384-72-7
• Molecular Formula: C₉H₈F₂O
• Molecular Weight: 170.16
• EINECS: 245-627-2
• Product Categories: Phenyls & Phenyl-Het;Miscellaneous;Phenyls & Phenyl-Het
• Mol File: 23384-72-7.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 65 °C
• Flash Point: 64-65°C/1.8mm
• Appearance: /
• Density: 1.166±0.06 g/cm3 (20 ºC 760 Torr)
• Vapor Pressure: 0.0886mmHg at 25°C
• Refractive Index: 1.488
• Storage Temp.: Sealed in dry,Room Temperature
• BRN: 2088650
• CAS DataBase Reference: 3',4'-DIFLUOROPROPIOPHENONE(CAS DataBase Reference)
• NIST Chemistry Reference: 3',4'-DIFLUOROPROPIOPHENONE(23384-72-7)
• EPA Substance Registry System: 3',4'-DIFLUOROPROPIOPHENONE(23384-72-7)

Safety Data

• Hazard Codes: Xi,Xn
• Statements: 36/37/38-22
• Safety Statements: 26-36-36/37
• HazardClass: IRRITANT
• Hazardous Substances Data: 23384-72-7(Hazardous Substances Data)

Usage

General Description

3',4'-Difluoropropiophenone is a chemical compound with the molecular formula C9H8F2O. It is a white solid with a melting point of 27-29°C and a boiling point of 223-224°C. 3',4'-DIFLUOROPROPIOPHENONE is commonly used as a building block in the synthesis of pharmaceuticals and other organic compounds. It is a ketone that contains two fluorine atoms attached to the third and fourth carbon atoms of the propiophenone molecule. 3',4'-Difluoropropiophenone exhibits various chemical reactivity and is utilized as an intermediate in the production of various drugs and organic compounds.

InChI:InChI=1/C9H8F2O/c1-2-9(12)6-3-4-7(10)8(11)5-6/h3-5H,2H2,1H3

Upstream product

• 367-11-3 ortho-difluorobenzene 
• 79-03-8 propionyl chloride 
• 34036-07-2 3,4 difluorobenzaldehyde 
• 369-33-5 3',4'-difluoroacetophenone 
• 68-12-2 N,N-dimethyl-formamide 

Downstream Products

• 847448-07-1 {[1-(3,4-difluoro-phenyl)-propyl]-formyl-amino}-acetic acid methyl ester 
• 742107-64-8 3-[1-(3,4-difluoro-phenyl)-propyl]-2-mercapto-3H-imidazole-4-carbonyl chloride 
• 742107-83-1 3-[1-(3,4-difluoro-phenyl)-propyl]-2-mercapto-3H-imidazole-4-carboxylic acid 
• 742107-80-8 3-[1-(3,4-difluoro-phenyl)-propyl]-2-mercapto-3H-imidazole-4-carboxylic acid methyl ester 
• 309720-84-1 1-(3-fluoro-4-morpholinophenyl)propan-1-one 

Relevant articles and documents

Discovery, Optimization, and Target Identification of Novel Potent Broad-Spectrum Antiviral Inhibitors

Viral infections are increasing and probably long-lasting global risks. In this study, a chemical library was exploited by phenotypic screening to discover new antiviral inhibitors. After optimizations from hit to lead, a novel potent small molecule (RYL-634) was identified, showing excellent broad-spectrum inhibition activity against various pathogenic viruses, including hepatitis C virus, dengue virus, Zika virus, chikungunya virus, enterovirus 71, human immunodeficiency virus, respiratory syncytial virus, and others. The mechanism of action and potential targets of RYL-634 were further explored by the combination of activity-based protein profiling and other techniques. Finally, human dihydroorotate dehydrogenase was validated as the major target of RYL-634. We did not observe any mutant resistance under our pressure selections with RYL-634, and it had a strong synergistic effect with some Food and Drug Administration-approved drugs. Hence, there is great potential for developing new broad-spectrum antivirals based on RYL-634.

Combination therapy for the treatment of benign prostatic hyperplasia

This invention relates to combination therapy for the treatment of benign prostatic hyperplasia comprising an alpha-1a antagonist and an endothelin antagonist. More specifically, the use of a selective alpha-1a adrenergic receptor antagonist in combination with a subtype non-selective endothelin antagonist provides relief of lower urinary tract symptoms in patients with symptomatic prostatism or benign prostatic hyperplasia. This combination therapy improves lower urinary tract symptoms including increasing urine flow rate, decreasing residual urine volume and improving overall obstructive and irritative symptoms in patients with benign prostatic hyperplasia or symptomatic prostatism.